Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
8-K
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
8-K
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
8-K
Liquidia Corporation Reports Second Quarter 2026 Financial Results
8-K
Liquidia Corporation Announces Results of 2026 Annual Meeting of Stockholders
8-K
Liquidia Corporation to be Added to the S&P SmallCap 600® Index
Prospectus
TYPE
HEADLINE
FILED AT
Registrations
TYPE
HEADLINE
FILED AT
S-3ASR
March 2026 SHELF
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
S-3
Form S-3 - Registration statement under Securities Act of 1933
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
DEF 14A
Form DEF 14A - Other definitive proxy statements
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
DEF 14A
Form DEF 14A - Other definitive proxy statements
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
